Regen BioPharma, Inc.
RGBP
$0.0548
$0.00479.38%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 59.10K | 59.10K | 59.40K | 59.10K | 59.10K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 59.10K | 59.10K | 59.40K | 59.10K | 59.10K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 59.10K | 59.10K | 59.40K | 59.10K | 59.10K |
| SG&A Expenses | 172.40K | 120.40K | 112.20K | 134.50K | 120.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 172.40K | 120.40K | 145.70K | 167.00K | 160.10K |
| Operating Income | -113.30K | -61.40K | -86.40K | -108.00K | -101.10K |
| Income Before Tax | -19.40K | -515.40K | -264.90K | -130.10K | -122.50K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -19.40K | -515.40K | -264.90K | -130.10K | -122.50K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.40K | -515.40K | -264.90K | -130.10K | -122.50K |
| EBIT | -113.30K | -61.40K | -86.40K | -108.00K | -101.10K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 0.00 | -0.13 | -0.03 | -0.01 | -0.03 |
| Normalized Basic EPS | 0.00 | -0.08 | -0.02 | -0.01 | -0.02 |
| EPS Diluted | 0.00 | -0.13 | -0.03 | -0.01 | -0.03 |
| Normalized Diluted EPS | 0.00 | -0.08 | -0.02 | -0.01 | -0.02 |
| Average Basic Shares Outstanding | 21.55M | 4.11M | 9.04M | 8.43M | 4.11M |
| Average Diluted Shares Outstanding | 21.55M | 4.11M | 9.04M | 8.43M | 4.11M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |